Please assess the completion status of the following clinical trial:

Trial Title: Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Currently being treated with a PPI, but continue to experience GERD symptoms (such as heartburn) at least 2 times per week.~Exclusion Criteria:~* Known allergy or intolerance to TCA~* History of serious arrhythmia or use of anti-arrhythmics~* History of seizures~* Subjects with significant co-morbidity, e.g., cardiovascular, respiratory, urogenital, renal, gastrointestinal, hepatic, hematological, endocrine, neurologic or psychiatric~* With evidence or history of drug abuse within the past 6 months~* Erosive esophagitis, esophageal ulceration, peptic stricture, Barrett's esophagus or adenocarcinoma of the esophagus on endoscopy~* History of esophagogastric surgery~* Gastric or duodenal lesions (ulcer, tumor, etc.)~* Women who are pregnant or of childbearing age who are not on contraception~* Patients who are unwilling or unable to provide informed consent~* Insulin dependent diabetes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Rabeprazole morning/evening placebo bedtime (Type: PLACEBO_COMPARATOR): AciPhex 20 mg BID and once daily placebo
- Rabeprazole breakfast, placebo dinner and bedtime (Type: PLACEBO_COMPARATOR): AcipHex 20 mg once daily and BID placebo
- Rabeprazole breakfast, placebo dinner, nortriptyline bedtime (Type: ACTIVE_COMPARATOR): AcipHex 20 mg once daily, placebo once daily and nortriptyline once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).